Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TAZEMETOSTAT HYDROBROMIDE Cause Muscular weakness? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Muscular weakness have been filed in association with TAZEMETOSTAT HYDROBROMIDE (TAZVERIK). This represents 0.6% of all adverse event reports for TAZEMETOSTAT HYDROBROMIDE.

8
Reports of Muscular weakness with TAZEMETOSTAT HYDROBROMIDE
0.6%
of all TAZEMETOSTAT HYDROBROMIDE reports
1
Deaths
3
Hospitalizations

How Dangerous Is Muscular weakness From TAZEMETOSTAT HYDROBROMIDE?

Of the 8 reports, 1 (12.5%) resulted in death, 3 (37.5%) required hospitalization.

Is Muscular weakness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TAZEMETOSTAT HYDROBROMIDE. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does TAZEMETOSTAT HYDROBROMIDE Cause?

Off label use (298) Fatigue (292) Disease progression (267) Nausea (207) Product dose omission issue (183) Death (106) Diarrhoea (100) Decreased appetite (81) Asthenia (75) Vomiting (75)

What Other Drugs Cause Muscular weakness?

ADALIMUMAB (3,605) METHOTREXATE (2,813) RITUXIMAB (2,621) ATORVASTATIN (2,494) PREDNISONE (2,236) ETANERCEPT (2,207) DALFAMPRIDINE (1,916) TOCILIZUMAB (1,790) FINGOLIMOD (1,769) SECUKINUMAB (1,747)

Which TAZEMETOSTAT HYDROBROMIDE Alternatives Have Lower Muscular weakness Risk?

TAZEMETOSTAT HYDROBROMIDE vs TAZOBACTAM TAZEMETOSTAT HYDROBROMIDE vs TBO-FILGRASTIM TAZEMETOSTAT HYDROBROMIDE vs TEBENTAFUSP-TEBN TAZEMETOSTAT HYDROBROMIDE vs TECFIDERA TAZEMETOSTAT HYDROBROMIDE vs TECHNETIUM TC-99M

Related Pages

TAZEMETOSTAT HYDROBROMIDE Full Profile All Muscular weakness Reports All Drugs Causing Muscular weakness TAZEMETOSTAT HYDROBROMIDE Demographics